Search Results for "Ofirmev"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Ofirmev. Results 1 to 7 of 7 total matches.
See also: acetaminophen

Intravenous Acetaminophen (Ofirmev)

   
The Medical Letter on Drugs and Therapeutics • Apr 04, 2011  (Issue 1361)
Intravenous Acetaminophen (Ofirmev) ...
The FDA has approved an intravenous (IV) formulation of acetaminophen (Ofirmev – Cadence) for use in patients ≥2 years old for management of pain either as monotherapy (mild to moderate pain) or with an opioid (moderate to severe pain) and for reduction of fever.
Med Lett Drugs Ther. 2011 Apr 4;53(1361):26-8 |  Show IntroductionHide Introduction

Intravenous Diclofenac (Dyloject)

   
The Medical Letter on Drugs and Therapeutics • Dec 21, 2015  (Issue 1484)
with longer use. Acetaminophen is available in an IV formulation (Ofirmev) that is infused over 15 minutes ...
The FDA has approved Dyloject (Hospira), an IV formulation of the NSAID diclofenac sodium, for use in adults. It can be administered alone for treatment of mild to moderate pain or in combination with opioid analgesics for moderate to severe pain. Dyloject is the first injectable formulation of diclofenac to become available in the US.
Med Lett Drugs Ther. 2015 Dec 21;57(1484):171-2 |  Show IntroductionHide Introduction

FDA Warns Against Use of Codeine and Tramadol in Children and Breastfeeding Women

   
The Medical Letter on Drugs and Therapeutics • May 22, 2017  (Issue 1521)
in oral and IV (Ofirmev) formulations.12 Oral oxycodone and hydrocodone are alternatives to codeine ...
The FDA has issued new warnings about the use of the opioid analgesics codeine and tramadol in children, particularly those <12 years old, and in breastfeeding women due to concerns about the risk of respiratory depression and death. The FDA previously issued warnings about these drugs in 2013 and 2015.
Med Lett Drugs Ther. 2017 May 22;59(1521):86-8 |  Show IntroductionHide Introduction

IV Meloxicam (Anjeso) for Pain

   
The Medical Letter on Drugs and Therapeutics • Jun 29, 2020  (Issue 1601)
of ketorolac, ibuprofen (Caldolor), and acetaminophen (Ofirmev) are also available for treatment of pain ...
The FDA has approved Anjeso (Baudax Bio), an IV formulation of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam, for once-daily treatment of moderate to severe pain in adults. Oral meloxicam (Mobic, and others), which is only indicated for treatment of chronic pain associated with osteoarthritis or rheumatoid arthritis, has been available for 20 years. IV formulations of ketorolac, ibuprofen (Caldolor), and acetaminophen (Ofirmev) are also available for treatment of pain.
Med Lett Drugs Ther. 2020 Jun 29;62(1601):100-2 |  Show IntroductionHide Introduction

Comparison Table: Some Nonopioid Analgesics for Pain (online only)

   
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022  (Issue 1645)
Analgesic Dosage1 Class Adverse Effects Comments Cost2 Acetaminophen – generic Feverall (Taro) Ofirmev ...
View the Comparison Table: Some Nonopioid Analgesics for Pain
Med Lett Drugs Ther. 2022 Mar 7;64(1645):e40-3 |  Show IntroductionHide Introduction

Intravenous Acetaminophen/Ibuprofen (Combogesic IV)

   
The Medical Letter on Drugs and Therapeutics • Apr 29, 2024  (Issue 1701)
possible. 1. Intravenous acetaminophen (Ofirmev). Med Lett Drugs Ther 2011; 53:26. 2. Intravenous ...
The FDA has approved Combogesic IV (Hikma), an IV solution containing acetaminophen and ibuprofen, to treat mild to moderate pain (alone) or moderate to severe pain (in combination with an opioid) in adults when IV analgesia is considered clinically necessary. Single-drug IV solutions containing ibuprofen (Caldolor) and acetaminophen have been available in the US for years.
Med Lett Drugs Ther. 2024 Apr 29;66(1701):68-9   doi:10.58347/tml.2024.1701c |  Show IntroductionHide Introduction

Nonopioid Drugs for Pain

   
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022  (Issue 1645)
tabs4 1300 mg q8h NSAIDs 1.505 (max 4000 mg/day) Ofirmev (Mallinckrodt) 10 mg/mL IV soln ...
Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. For severe pain, especially severe chronic cancer pain, use of opioids may be necessary. Noninvasive nonpharmacologic treatments, including physical and psychological therapies, have been shown to improve pain and function in patients with some common chronic pain conditions and are unlikely to cause serious harms. A multimodal approach to analgesic therapy can increase pain control while reducing opioid use and adverse effects.
Med Lett Drugs Ther. 2022 Mar 7;64(1645):33-40 |  Show IntroductionHide Introduction